Covid-19 and Unaccounted Collateral Damage

Dr Metzler and collaborators carried out a retrospective search to find out the impact of the Covid-19 pandemic on diagnosis and treatment of acute coronary syndromes during March 2020 in Austria. Basically, they tried to account for the collateral damage we all imagine, but no government reports. 

COVID-19 y el daño colateral que nadie contabiliza

During March we observed a significant drop in the number of ACS patients admitted to the emergency rooms. This drop is close to 40% and is even bigger when it comes to Non-STEMI patients.

It came as a surprise to the authors, who had speculated with an increase in the number of cases, according to their experience with other viral infections, natural disasters, or profound financial crisis. We could say Covid-19 is a combination of all three.

The strict health care protocols that undoubtedly helped and keep helping to control this pandemic might have unintentionally affected the attention paid to other diseases. 


Read also: Special Articles on COVID-19.


ACS symptoms such as dyspnea and chest discomfort might easily be mistaken for acute respiratory infections. 

In addition, strict instructions to stay at home and fear of catching the disease might have caused many patients to avoid hospitals despite clearly manifesting symptoms. 

Regardless possible reasons and speculations, the smaller number of patients being treated will eventually translate into increased early and late cardiovascular mortality. This is the unaccounted, and therefore unreported, death toll no government will address.


Read also: Cardiovascular Sequelae Associated with COVID-19.


Compared against similar periods in a pre-pandemic context, and considering  1950 MI mortality rates (times we had nothing to offer, just like the present context, with untreated CAD patients undergoing an ACS at home) we can easily assume there have been 110 unaccounted ACS deaths during March alone for a population of 8.8 million people, such as Austria’s.

The government of Austria has informed 86 deaths due to coronavirus in this same month. However, collateral damage from the virus protocols can be worse yet than the virus itself. 

Original Title: Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage.

Reference: Bernhard Metzler et al. European Heart Journal (2020) 41, 1852–1853. doi:10.1093/eurheartj/ehaa314.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...